<DOC>
	<DOC>NCT01243151</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.</brief_summary>
	<brief_title>Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>LDLC must be greater or equal to 130 mg/dl BMI must be between 18.5 and 40 kg/m2 Japanese volunteers must have 4 Japanese grand parents born in Japan History of cardiovascular or cerebrovascular event during the past year. Poorly controlled type 1 or type 2 diabetes mellitus Subjects who have taken lipid lowering therapies within the last 3 months of screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>LDL</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Japanese Volunteers</keyword>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>